WO2006103472A3 - Soluble vox2 protein as immunoregulatory factor - Google Patents

Soluble vox2 protein as immunoregulatory factor Download PDF

Info

Publication number
WO2006103472A3
WO2006103472A3 PCT/GB2006/001219 GB2006001219W WO2006103472A3 WO 2006103472 A3 WO2006103472 A3 WO 2006103472A3 GB 2006001219 W GB2006001219 W GB 2006001219W WO 2006103472 A3 WO2006103472 A3 WO 2006103472A3
Authority
WO
WIPO (PCT)
Prior art keywords
vox2
protein
soluble
immunoregulatory factor
immunoregulatory
Prior art date
Application number
PCT/GB2006/001219
Other languages
French (fr)
Other versions
WO2006103472A2 (en
Inventor
David J Blackbourn
Seyyed Abdolrahim Razaee
Original Assignee
Univ Glasgow
David J Blackbourn
Seyyed Abdolrahim Razaee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Glasgow, David J Blackbourn, Seyyed Abdolrahim Razaee filed Critical Univ Glasgow
Priority to JP2008503600A priority Critical patent/JP2008537743A/en
Priority to AU2006228351A priority patent/AU2006228351A1/en
Priority to EP06726623A priority patent/EP1871412A2/en
Publication of WO2006103472A2 publication Critical patent/WO2006103472A2/en
Publication of WO2006103472A3 publication Critical patent/WO2006103472A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides soluble derivatives of the vOX2 protein encoded by Kaposi’s sarcoma-associated herpesvirus (KSHV), and their use for the treatment of inflammatory disorders such as autoimmune diseases, allergy and graft rejection.
PCT/GB2006/001219 2005-04-01 2006-04-03 Soluble vox2 protein as immunoregulatory factor WO2006103472A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2008503600A JP2008537743A (en) 2005-04-01 2006-04-03 Soluble immune regulator
AU2006228351A AU2006228351A1 (en) 2005-04-01 2006-04-03 Soluble vOX2 protein as immunoregulatory factor
EP06726623A EP1871412A2 (en) 2005-04-01 2006-04-03 Soluble vox2 protein as immunoregulatory factor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0506721.0 2005-04-01
GBGB0506721.0A GB0506721D0 (en) 2005-04-01 2005-04-01 Soluble immunoregulatory factor

Publications (2)

Publication Number Publication Date
WO2006103472A2 WO2006103472A2 (en) 2006-10-05
WO2006103472A3 true WO2006103472A3 (en) 2007-02-22

Family

ID=34586601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/001219 WO2006103472A2 (en) 2005-04-01 2006-04-03 Soluble vox2 protein as immunoregulatory factor

Country Status (6)

Country Link
EP (1) EP1871412A2 (en)
JP (1) JP2008537743A (en)
CN (1) CN101184505A (en)
AU (1) AU2006228351A1 (en)
GB (1) GB0506721D0 (en)
WO (1) WO2006103472A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2905651C (en) * 2013-03-13 2019-01-15 Becton, Dickinson And Company A method for improving analysis of microorganisms in complex matrices

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086011A1 (en) * 1997-11-07 2002-07-04 Reginald Gorczynski Methods and compositions for modulating autoimmunity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086011A1 (en) * 1997-11-07 2002-07-04 Reginald Gorczynski Methods and compositions for modulating autoimmunity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FOSTER-CUEVAS MILDRED ET AL: "Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor", JOURNAL OF VIROLOGY, vol. 78, no. 14, July 2004 (2004-07-01), pages 7667 - 7676, XP002392999, ISSN: 0022-538X *
GORCZYNSKI R M ET AL: "An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 163, no. 3, 1 August 1999 (1999-08-01), pages 1654 - 1660, XP002222032, ISSN: 0022-1767 *
GORCZYNSKI R M ET AL: "CD200 immunoadhesin suppresses collagen-induced arthritis in mice", CLINICAL IMMUNOLOGY, ACADEMIC PRESS,, US, vol. 101, no. 3, December 2001 (2001-12-01), pages 328 - 334, XP002264320, ISSN: 1521-6616 *
PRESTON S ET AL: "THE LEUKOCYTE/NEURON CELL SURFACE ANTIGEN OX2 BINDS TO A LIGAND ON MACROPHAGES", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 27, no. 8, August 1997 (1997-08-01), pages 1911 - 1918, XP000952951, ISSN: 0014-2980 *
REZAEE S A RAHIM ET AL: "Inhibition of neutrophil function by the Kaposi's sarcoma-associated herpesvirus vOX2 protein", AIDS (HAGERSTOWN), vol. 19, no. 16, November 2005 (2005-11-01), pages 1907 - 1910, XP002393000, ISSN: 0269-9370 *
TALBOT S J ET AL: "Transcriptional Analysis of Human Herpesvirus-8 Open Reading Frames 71, 72, 73, K14, and 74 in a Primary Effusion Lymphoma Cell Line", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 257, no. 1, 25 April 1999 (1999-04-25), pages 84 - 94, XP004440107, ISSN: 0042-6822 *

Also Published As

Publication number Publication date
WO2006103472A2 (en) 2006-10-05
AU2006228351A1 (en) 2006-10-05
EP1871412A2 (en) 2008-01-02
GB0506721D0 (en) 2005-05-11
CN101184505A (en) 2008-05-21
JP2008537743A (en) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2006058868A3 (en) Substituted pteridines for treating inflammatory diseases
WO2006058867A3 (en) Substituted pteridines for the treatment of inflammatory diseases
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
EP2532657A3 (en) Compounds and methods of use
WO2007007173A3 (en) Human anti-madcam antibodies
WO2006124748A3 (en) Multicyclic compounds and methods of their use
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2007147019A3 (en) Il-17 and il-23 antagonists and methods of using the same
WO2005072223A3 (en) Engineered proteins, and methods of making and using
EP2450360A3 (en) (S)-N-Methylnaltrexone
WO2006029385A3 (en) Quinazoline derivatives as metabolically inert antifolate compounds.
WO2006119329A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2006058869A8 (en) Substituted pteridines for treating inflammatory diseases
IN2005DE03350A (en)
WO2008029276A8 (en) Compositions and methods for the treatment of ophthalmic disease
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
IL173123A0 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
EP2772260A3 (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
WO2007068750A3 (en) Immunoglobulins directed against nogo
WO2005074375A3 (en) Heparanase inhibitors and uses thereof
WO2005030144A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
WO2007135026A3 (en) Substituted pteridines as therapeutic agents
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008503600

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006726623

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006228351

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 4059/KOLNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

ENP Entry into the national phase

Ref document number: 2006228351

Country of ref document: AU

Date of ref document: 20060403

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006228351

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680018907.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006726623

Country of ref document: EP